DAFTAR PUSTAKA

1. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al, 2018. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & Diseases (2018) 5(1): 77-106.

2. World Health Organization International Agency for Research on Cancer (IARC), 2020. GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence in Indonesia. GLOBOCAN (2020).

3. Kementerian Kesehatan Republik Indonesia, 2018. Pedoman Nasional Pelayanan Kedokteran Tatalaksana Kanker Payudara. (2018) 2.

4. Iqbal N, Iqbal N, 2014. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int (2014): 1-9

5. Wolff AC, Elizabeth Hale Hammond M, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al, 2018. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ college of American pathologists clinical practice guideline focused update. J Clin Oncol (2018) 36(20): 2105-22.

6. Qian XL, Wen HY, Yang YL, Gu F, Guo XJ, Liu FF, et al, 2016. Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines. Breast Cancer Res Treat (2016) 159(1): 31-39.

7. Nguyen D, Yu J, Reinhold WC, Yang SX, 2020. Association of Independent Prognostic Factors and Treatment Modality with Survival and Recurrence Outcomes in Breast Cancer. JAMA Netw Open (2020) 3(7):1–11.

8. Cong TD, Thanh TN, Phan QAN, Thi APH, Tran BSN, Vu QHN, 2020. Correlation between HER2 expression and clinicopathological features of breast cancer: A cross-sectional study in Vietnam. Asian Pacific J Cancer Prev (2020) 21(4): 1135-42.

9. Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al, 2019. HER2 overexpression and correlation with other significant clinicopathologic

parameters in Ivorian breast cancer women 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. BMC Clin Pathol (2019) 19(1):1–6.

10. Shokouh TZ, Ezatollah A, Barand P, Yang F, 2015. Interrelationships between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: Retrospective-observational analytical study. Med (United States) (2015) 94(32):1–6.

11. Shi P, Chen C, Yao Y, 2019. Correlation Between HER-2 Gene Amplification or Protein Expression and Clinical Pathological Features of Breast Cancer. Cancer Biother Radiopharm (2019) 34(1):42–6.

12. Bartlett JMS, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, et al, 2007. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) - negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol (2007) 25(28):4423–30.

13. He KW, Sun JJ, Liu ZB, Zhuo PY, Ma QH, Liu ZY, et al, 2017. Prognostic significance of lymphatic vessel invasion diagnosed by D2-40 in Chinese invasive breast cancers. Med (United States) (2017) 96(44).

14. Houvenaeghel G, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, et al. Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. ESMO Open (2021) 6(6)

15. Derrickson BH, Tortora GJ. Principles of Anatomy and Physiology. 11th ed. New Jersey: Wiley; 2014.

16. Rivard AB, Galarza-Paez L, Peterson DC, 2021. Anatomy, Thorax Breast. StatPearls (2021).

17. Canul-Medina G, Fernandez-Mejia C, 2019. Morphological , hormonal , and molecular changes in different maternal tissues during lactation and post - lactation. J Physiol Sci (2019) 69(6): 825-35.

18. Javed A, Lteif A, 2013. Development of the human breast. Semin Plast Surg (2013) 27(1): 5-12.

19. Mescher AL, Junqueira LCU. Junqueira's Basic Histology Text and Atlas. 13th ed. New York: McGraw-Hill Medical; 2013.

20. What Is Breast Cancer? [Internet]. American Cancer Society (2019).

21. What Is Breast Cancer? [Internet]. Centers for Disease Control and Prevention (2020).

22. Cancer Statistics [Internet]. National Cancer Institute (2020).

23. Breast Cancer [Internet]. World Health Organzation (2021).

24. Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, et al, 2019. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat (2019) 173(1): 37-48.

25. Thakur P, Seam RK, Gupta MK, Gupta M, Mukesh S, Fotedar V, 2017. Breast cancer risk factor evaluation in a Western Himalayan state: A case-control study and comparison with the Western World. South Asian J cancer (2017) 6(3): 106-109.

26. Shah R, Rosso K, David Nathanson S, 2014. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol (2014) 5(3): 283-98.

27. Momenimovahed Z, Salehiniya H, 2019. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer Targets Ther (2019) 11: 151-64.

28. Alkabban FM, Ferguson T, 2021. Breast Cancer. StatPearls (2021).

29. Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E, 2015. Breast cancer risk factors. Prz Menopauzalny (2015) 14(3): 196-202.

30. Laamiri FZ, Bouayad A, Hasswane N, Ahid S, Mrabet M, Amina B, 2015. Risk Factors for Breast Cancer of Different Age Groups: Moroccan Data. Open J Obstet Gynecol (2015) 5(2): 79-87.

31. Bardaweel SK, Akour AA, Al-Muhaissen S, Alsalamat HA, Ammar K, 2019. Oral contraceptive and breast cancer: Do benefits outweigh the risks? A case - Control study from Jordan. BMC Womens Health (2019) 19(1): 1-7.

32. Chaveepojnkamjorn W, Pichainarong N, Thotong R, Sativipawee P, Pitikultang S. Relationship between breast cancer and oral contraceptive use among Thai premenopausal women: A case-control study. Asian Pacific J Cancer Prev (2017) 18(5): 1429-33.

33. Beaber EF, Buist DSM, Barlow WE, Malone KE, Reed SD, Li CI, 2014. Recent oral contraceptive use by formulation and breast cancer risk among women 20–49 years of age. Cancer Res (2014) 74(15):4078–89.

34. Soewoto W, Mudigdo A, Aryandono T, Dirgahayu P , 2018. Correlation between duration of estrogen exposure with grading of breast cancer. Bali Med J (2018) 7(3):778–81.

35. Tin Tin S, Reeves GK, Key TJ, 2021. Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank. Br J Cancer(2021) 125(1): 126-34.

36. Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, et al, 2017. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. J Natl Cancer Inst (2017) 109(9): 1-7.

37. Li Y, Ma L, 2020. Exposure to solar ultraviolet radiation and breast cancer risk A dose-response meta-analysis. Med (United States) (2020) 99(45).

38. Chen MJ, Wu WYY, Yen AMF, Fann JCY, Chen SLS, Chiu SYH, et al, 2016. Body mass index and breast cancer: Analysis of a nation-wide population-based prospective cohort study on 1 393 985 Taiwanese women. Int J Obes (2016) 40(3):524–30.

39. Park SY, Kolonel LN, Lim U, White KK, Henderson BE, Wilkens LR, 2014. Alcohol consumption and breast cancer risk among women from five ethnic groups with light to moderate intakes: The Multiethnic Cohort Study. Int J Cancer (2014) 134(6):1504–10.

40. Luo J, Margolis KL, Wactawski-Wende J, Horn K, Messina C, Stefanick ML, et al, 2011. Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. BMJ (2011) 342.

41. Tong JH, Li Z, Shi J, Li HM, Wang Y, Fu LY, et al, 2014. Passive smoking exposure from partners as a risk factor for ER +/PR+ double positive breast cancer in never-smoking Chinese urban women: A hospital-based matched case control study. PLoS One (2014) 9(5).

42. Kispert S, McHowat J, 2017. Recent insights into cigarette smoking as a lifestyle risk factor for breast cancer. Breast Cancer Targets Ther (2017) 9:127–32.

43. Dandamudi A, Tommie J, Nommsen-Rivers L, Couch S, 2018. Dietary patterns and breast cancer risk: A systematic review. Anticancer Res (2018) 38(6): 3209–22.

44. Kabel AM, Baali FH, 2015. Breast Cancer: Insights into Risk Factors, Pathogenesis, Diagnosis and Management. J Cancer Res Treat (2015) 3(2): 28-33

45. WHO Classification of Tumours Editorial Board, 2020. The 2019 World Health Organization classification of tumours of the breast. Histopathology. (2020) 77(2):181–5.

46. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK, 2010. Various Types And Management Of Breast Cancer: An Overview. J Adv Pharm Technol Res. (2010) 1(2):109–26.

47. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart MJ, et al, 2015. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol (2015) 26(8):1533–46.

48. Watkins EJ, 2019. Overview of breast cancer. J Am Acad Physician Assist (2019) 32(10):13–7.

49. Atanda AT, Mam MI, Umar AB, Yusuf I, Bello SS, 2017. Audit of Nottingham System Grades Assigned to Breast Cancer Cases in a Teaching Hospital. Ann Trop Pathol (2017) 8(2): 104–7.

50. Kabel AM, 2017. Tumor markers of breast cancer: New prospectives. J Oncol Sci (2017) 3(1): 5–11.

51. Fuentes N, Silveyra P, 2016. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol (2016) 166:135–70.

52. Hamilton KJ, Hewitt SC, Arao Y, Korach KS, 2017. Estrogen Hormone Biology. Curr Top Dev Biol (2017) 125:109–46.

53. Jacobsen BM, Horwitz KB, 2012. Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol (2012) 357(1–2):18–29.

54. Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA, 2015. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol (2015) 54(2):31–53.

55. Ishikawa T, Ichikawa Y, Shimizu D, Sasaki T, Tanabe M, Chishima T, et al, 2014. The role of HER-2 in Breast Cancer. J Surg Sci (2014) 2(1):4–9.

56. Furrer D, Sanschagrin F, Jacob S, Diorio C, 2015. Advantages and disadvantages of technologies for HER2 Testing in Breast Cancer Specimens. Am J Clin Pathol (2015) 144(5):686–703.

57. Gutierrez C, Schiff R, 2011. HER2: Biology, detection, and clinical implications. Arch Pathol Lab Med (2011135(1):55–62.

58. Wang K, Ren Y, Li H, Zheng K, Jiang J, Zou T, et al, 2016. Comparison of clinicopathological features and treatments between young (≤40 years) and older (>40 years) female breast cancer patients in West China: A retrospective, epidemiological, multicenter, case only study. PLoS One (2016) 11(3):1–14.

59. Ryu YJ, Kang SJ, Cho JS, Yoon JH, Park MH, 2018. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy. Med (United States) (2018) 97(30).

60. Ahn S, Woo JW, Lee K, Park SY, 2020. HER2 status in breast cancer: Changes in guidelines and complicating factors for interpretation. J Pathol Transl Med (2020) 54(1):34–44.